Global Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431765
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Baxalta
  • Biogen Idec, Inc.
  • CSL Behring
  • Genentech, Inc.
  • Kedrion
  • Octapharma AG
  • MORE
Hemophilia Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global hemophilia treatment market was valued at US$ 10,042.7 Mn in 2016, and is expected to reach US$ 15,124.7 Mn by 2025, expanding at a CAGR of 4.5% from 2017 to 2025.

Market Insights

According to a study by the National Hemophilia Foundation (U.S.), around 0.4million people across the world suffer from hemophilia. Out of the total prevalent population of hemophilia, approximately only 25% receives proper treatment. The World Federation of Hemophilia is striving to bridge this gap through educating patients and general population and conducting various programs. Lack of awareness about bleeding disorders and limited access to treatment have so far hindered the growth of hemophilia treatment market. However, rise in funding for research and development, increasing healthcare expenditure, advancement in diagnostic technology would propel the growth of hemophilia treatment market. The World Federation of Hemophilia and WHO both recommend prophylaxis as the optimal therapy for hemophilia. Across North America, Europe and Japan, prophylactic therapies are being widely used. Furthermore, increase in demand on prophylactic treatment and with availability of recombinant factor provides immense growth opportunities of hemophilia market.

The global hemophilia treatment market is segmented by product type into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents and desmopressin. Recombinant coagulation factors are preferred by most physicians, due to low risk of blood borne infection. Thus the segment is anticipated to drive the haemophilia market in the given forecast period. The global hemophilia treatment market is segmented by hemophilia type into Hemophilia A, Hemophilia B and others. Hemophilia A occupies the largest market share of global hemophilia market due to rising prevalence of hemophilia A and surge in demand of prophylactic treatment.

As of the current market scenario, North America dominates the global hemophilia treatment market followed by the Europe. The factors driving the North America hemophilia market are rising number of cases of hemophilia, awareness about disease, availability of recombinant products, advanced diagnostic technology and increasing prophylactic treatments. Asia Pacific is the fastest growing regional market for hemophilia treatment due to improving healthcare infrastructure, awareness about bleeding disorders and overall impetus due to emerging economies such as China and India.

Market Competition Assessment

Key players in the global hemophilia market are Baxter International, Inc., Baxalta, Bayer AG, Biogen Idec, Inc., Chugai Pharmaceutical Co., CSL Behring, Genentech, Inc., Hospira, Inc., Ferring B.V., Kedrion, Octapharma AG, Novo Nordisk, Pfizer, Inc., Sanofi SA, Swedish Orphan Biovitrum AB, Shire Plc. and others.

Key Market Movements:
  • Rising prevalence of hemophilia, with estimate of about 400,000 individuals affected by the disease. Around 75% of people do not receive required treatment for hemophilia.
  • Rising awareness about hemophilia and other bleeding disorders among people due to various programs conducted by international and national bodies and pharmaceutical companies. Development of novel treatment options and educational program to holistically address the unmet need of the patients and care givers.
  • Focus on prophylactic treatment, growing market for recombinant products, advancement in diagnostic technology further boosting the demand for hemophilia market
  • Promising late-stage pipeline product contains long-acting replacement therapies and non-factor therapies that would receive approval during forecast period, which would drive the hemophilia market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxalta
  • Biogen Idec, Inc.
  • CSL Behring
  • Genentech, Inc.
  • Kedrion
  • Octapharma AG
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Hemophilia Treatment Market Portraiture
2.1.1. Global Hemophilia Treatment Market, by Product Type, 2016
2.1.2. Global Hemophilia Treatment Market, by Hemophilia Type, 2016
2.1.3. Global Hemophilia Treatment Market, by Geography, 2016

Chapter 3. Hemophilia Treatment: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Hemophilia Treatment Market, by Product Type
4.3. Plasma Derived Coagulation Factor Concentrates
4.3.1. Factor VIII
4.3.2. Factor IX
4.3.3. Combination
4.4. Recombinant Coagulation Factor Concentrates
4.4.1. Factor VIII
4.4.2. Factor IX
4.4.3. Combination
4.5. Antifibrinolytic Agents
4.6. Desmopressin

Chapter 5. Global Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
5.1. Overview
5.2. Attractive Investment Proposition: Global Hemophilia Treatment Market, by Hemophilia Type
5.3. Hemophilia A
5.4. Hemophilia B
5.5. Others

Chapter 6. Global Hemophilia Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
6.1. Overview
6.2. North America Hemophilia Treatment Market Analysis, 2015 - 2025
6.2.1. North America Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
6.2.2. North America Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
6.2.3. North America Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Hemophilia Treatment Market Analysis, 2015 - 2025
6.3.1. Europe Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
6.3.2. Europe Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
6.3.3.
6.3.4. Europe Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.3.4.1. U.K.
6.3.4.2. Germany
6.3.4.3. France
6.3.4.4. Rest of Europe
6.4. Asia Pacific Hemophilia Treatment Market Analysis, 2015 - 2025
6.4.1. Asia Pacific Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
6.4.2. Asia Pacific Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
6.4.3. Asia Pacific Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Hemophilia Treatment Market Analysis, 2015 - 2025
6.5.1. Latin America Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
6.5.2. Latin America Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
6.5.3. Latin America Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Hemophilia Treatment Market Analysis, 2015 - 2025
6.6.1. MEA Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
6.6.2. MEA Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
6.6.3. MEA Hemophilia Treatment Market, by Region, 2015 - 2025 (US$ Mn)
6.6.3.1. UAE
6.6.3.2. Saudi Arabia
6.6.3.3. South Africa
6.6.3.4. Rest of MEA

Chapter 7. Company Profiles
7.1. Baxter International, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Baxalta
7.3. Bayer AG
7.4. Biogen Idec, Inc.
7.5. Chugai Pharmaceutical Co.
7.6. CSL Behring
7.7. Genentech, Inc.
7.8. Hospira, Inc.
7.9. Ferring B.V.
7.10. Kedrion
7.11. Octapharma AG
7.12. Novo Nordisk
7.13. Pfizer, Inc.
7.14. Sanofi SA
7.15. Swedish Orphan Biovitrum AB
7.16. Shire Plc.
7.17. Other Notable Players

List of Figures
Fig. 1 Hemophilia Treatment: Market Segmentation
Fig. 2 Global Hemophilia Treatment Market, by Product Type, 2016 (US$ Mn)
Fig. 3 Global Hemophilia Treatment Market, by Hemophilia Type, 2016 (US$ Mn)
Fig. 4 Global Hemophilia Treatment Market Share, by Geography, 2016 (Value %)
Fig. 5 Attractive Investment Proposition, by Geography
Fig. 6 Market Competition Landscape, by Key Players, 2016
Fig. 7 Global Plasma Derived Coagulation Factor VIII Concentrates Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Plasma Derived Coagulation Factor IX Concentrates Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Plasma Derived Coagulation Combination Concentrates Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Recombinant Coagulation Factor VIII Concentrates Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Recombinant Coagulation Factor XI Concentrates Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global Recombinant Coagulation Combination Concentrates Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Antifibrinolytic Agents Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 14 Global Desmopressin Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 15 U.S. Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 16 Canada Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 17 U.K. Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 18 Germany Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 19 France Hemophilia Treatment Market, 2015-2025 (US$ Mn)
Fig. 20 Rest of Europe Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 21 Japan Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 22 China Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 23 India Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 24 Rest of Asia Pacific Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 25 Brazil Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 26 Mexico Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 27 Rest of Latin America Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 28 UAE Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 29 Saudi Arabia Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 30 South Africa Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 31 Rest of Middle East and Africa Hemophilia Treatment Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
Table 2 North America Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
Table 3 North America Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
Table 4 North America Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 5 Europe Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
Table 6 Europe Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
Table 7 Europe Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 8 Asia Pacific Hemophilia Treatment Market, by Product Type, 2015 - 2025(US$ Mn)
Table 9 Asia Pacific Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025(US$ Mn)
Table 10 Asia Pacific Hemophilia Treatment Market, by Country, 2015 - 2025(US$ Mn)
Table 11 Latin America Hemophilia Treatment Market, by Product Type, 2015 - 2025(US$ Mn)
Table 12 Latin America Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025(US$ Mn)
Table 13 Latin America Hemophilia Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 14 Middle East and Africa Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
Table 15 Middle East and Africa Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
Table 16 Middle East and Africa Hemophilia Treatment Market, by Region, 2015 - 2025 (US$ Mn)
Table 17 Baxter International, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 18 Baxalta: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 19 Bayer AG: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 20 Biogen Idec, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 21 Chugai Pharmaceutical Co.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 22 CSL Behring: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 23 Genentech, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 24 Hospira, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 25 Ferring B.V: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 26 Kedrion: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 27 Octapharma AG: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 28 Novo Nordisk: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 29 Pfizer, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 30 Sanofi SA: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 31 Swedish Orphan Biovitrum AB: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Table 32 Shire Plc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Baxter International, Inc.
  • Baxalta
  • Bayer AG
  • Biogen Idec, Inc.
  • Chugai Pharmaceutical Co.
  • CSL Behring
  • Genentech, Inc.
  • Hospira, Inc.
  • Ferring B.V.
  • Kedrion
  • Octapharma AG
  • Novo Nordisk
  • Pfizer, Inc.
  • Sanofi SA
  • Swedish Or
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll